$QLGN
Qualigen Therapeutics, Inc. Stock $qlgn

$qlgn Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223028465 Filed on August 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2023 Q2
Revenue	$0.00	$0.00	$1.627M
YoY Change	-100.0%	-100.0%	13.74%
Cost Of Revenue			$1.017M
YoY Change			1311.86%
Gross Profit			$610.5K
YoY Change			-55.06%
Gross Profit Margin			37.52%
Selling, General & Admin	$962.8K	$1.337M	$2.835M
YoY Change	-67.09%	-53.23%	-4.41%
% of Gross Profit			464.39%
Research & Development	$1.311M	$1.442M	$1.327M
YoY Change	-26.26%	-14.6%	-11.93%
% of Gross Profit			217.29%
Depreciation & Amortization	$4.500K	-$120.0K	$19.00K
YoY Change	-91.49%	-600.0%	-20.83%
% of Gross Profit			3.11%
Operating Expenses	$2.274M	$2.778M	$5.178M
YoY Change	-51.65%	-52.29%	-7.07%
Operating Profit		-$2.778M	-$3.551M
YoY Change		-36.61%	-14.25%
Interest Expense	-$235.8K	-$367.3K	-$377.4K
YoY Change	456.02%	-8032.18%	-7930.29%
% of Operating Profit
Other Income/Expense, Net	$663.1K	-$456.7K	$5.256K
YoY Change	-693.03%	-239.62%	-72.69%
Pretax Income	-$2.472M	-$3.235M	-$3.546M
YoY Change	-71.91%	-20.24%	-13.98%
Income Tax	-$4.790K		-$38.18K
% Of Pretax Income
Net Earnings	-$2.450M	-$3.695M	-$3.464M
YoY Change	-61.55%	-3.4%	-15.99%
Net Earnings / Revenue			-212.92%
Basic Earnings Per Share			-$0.69
Diluted Earnings Per Share	-$0.47	-$0.72	-$0.69
COMMON SHARES
Basic Shares Outstanding	5.181M shares	5.052M shares	5.052M shares
Diluted Shares Outstanding		5.052M shares	5.052M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$401.8K	$2.074M	$1.342M
YoY Change	-94.29%	-68.66%	-86.23%
Cash & Equivalents	$401.8K	$2.074M	$1.347M
Short-Term Investments
Other Short-Term Assets	$765.0K	$1.376M	$11.64K
YoY Change	5958.61%	-18.71%	-99.4%
Inventory			$1.563M
Prepaid Expenses
Receivables	$538.6K		$679.4K
Other Receivables			$0.00
Total Short-Term Assets	$1.167M	$3.450M	$4.863M
YoY Change	-89.22%	-66.82%	-64.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00		$498.6K
YoY Change	-100.0%		51.27%
Goodwill			$625.6K
YoY Change			-87.22%
Intangibles			$5.833M
YoY Change			-0.43%
Long-Term Investments
YoY Change
Other Assets	$866.5K	$866.5K	$18.33K
YoY Change	4626.08%	4626.09%	0.01%
Total Long-Term Assets	$866.5K	$866.5K	$8.287M
YoY Change	-89.51%	-93.1%	-34.46%
TOTAL ASSETS
Total Short-Term Assets	$1.167M	$3.450M	$4.863M
Total Long-Term Assets	$866.5K	$866.5K	$8.287M
Total Assets	$2.033M	$4.316M	$13.15M
YoY Change	-89.35%	-81.2%	-50.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.223M	$1.572M	$1.756M
YoY Change	159.3%	163.71%	91.24%
Accrued Expenses	$527.0K	$1.144M	$1.981M
YoY Change	-65.14%	-22.23%	40.01%
Deferred Revenue
YoY Change
Short-Term Debt	$1.299M	$0.00	$965.2K
YoY Change	36.66%	-100.0%	2.68%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.137M	$5.957M	$8.494M
YoY Change	-51.94%	22.03%	50.44%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities			$1.197M
YoY Change			-20.0%
Total Long-Term Liabilities	$0.00	$0.00	$1.197M
YoY Change	-100.0%	-100.0%	-20.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.137M	$5.957M	$8.494M
Total Long-Term Liabilities	$0.00	$0.00	$1.197M
Total Liabilities	$4.137M	$5.957M	$9.842M
YoY Change	-59.9%	-15.43%	24.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$116.8M	-$114.4M	-$110.7M
YoY Change	12.96%	17.94%	18.79%
Common Stock	$43.26K	$42.95K	$42.95K
YoY Change	2.74%	2.0%	10.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.104M	-$1.641M	$2.034M
YoY Change
Total Liabilities & Shareholders Equity	$2.033M	$4.316M	$13.15M
YoY Change	-89.35%	-81.2%	-50.09%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$2.450M	-$3.695M	-$3.464M
YoY Change	-61.55%	-3.4%	-15.99%
Depreciation, Depletion And Amortization	$4.500K	-$120.0K	$19.00K
YoY Change	-91.49%	-600.0%	-20.83%
Cash From Operating Activities	-$5.672M	$927.3K	-$2.928M
YoY Change	153.45%	-129.14%	-25.79%
INVESTING ACTIVITIES
Capital Expenditures			$48.41K
YoY Change			-449.53%
Acquisitions
YoY Change
Other Investing Activities	$235.4K	$3.981M	$0.00
YoY Change			-100.0%
Cash From Investing Activities	$235.4K	$4.231M	-$48.41K
YoY Change	-196.33%	-37671.4%	-139.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-110.0K	-440.0K	0.000
YoY Change	-103.79%	-13393.05%
NET CHANGE
Cash From Operating Activities	-5.672M	927.3K	-2.928M
Cash From Investing Activities	235.4K	4.231M	-48.41K
Cash From Financing Activities	-110.0K	-440.0K	0.000
Net Change In Cash	-5.546M	4.718M	-2.977M
YoY Change	-1416.6%	-247.9%	-22.17%
FREE CASH FLOW
Cash From Operating Activities	-$5.672M	$927.3K	-$2.928M
Capital Expenditures			$48.41K
Free Cash Flow			-$2.977M
YoY Change			-24.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Central Index Key EntityCentralIndexKey	0001460702
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense		usd
CY2022Q2	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense		usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense		usd
CY2022Q2	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		usd
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		usd
CY2023Q2	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal		usd
CY2022Q2	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal		usd
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal		usd
	QLGN	Loss On Voluntary Conversion Of Convertible Debt LossOnVoluntaryConversionOfConvertibleDebt		usd
	QLGN	Accretion Of Discount On Convertible Debt AccretionOfDiscountOnConvertibleDebt		usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
	QLGN	Increase Decrease In Research And Development Grant Liability IncreaseDecreaseInResearchAndDevelopmentGrantLiability		usd
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities		usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	QLGN	Transfers Of Inventory From Equipment Held For Lease TransfersOfInventoryFromEquipmentHeldForLease		usd
	QLGN	Fair Value Of Warrant Liabilities On Date Of Exercise FairValueOfWarrantLiabilitiesOnDateOfExercise		usd
	QLGN	Voluntary Conversion Of Convertible Debt Into Common Stock VoluntaryConversionOfConvertibleDebtIntoCommonStock		usd
CY2022Q4	QLGN	Preapaid Research And Development Expenses PreapaidResearchAndDevelopmentExpenses		usd
CY2023Q3	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P5Y
CY2023Q2	QLGN	Accrued Equipment Held For Lease AccruedEquipmentHeldForLease		usd
	QLGN	Fair Value Of Warrant Liabilities On Date Of Exercise FairValueOfWarrantLiabilitiesOnDateOfExercise		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum		pure
CY2023Q2	us-gaap	Share Price SharePrice
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	Qualigen Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity File Number EntityFileNumber	001-37428
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-3474527
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2042 Corte Del Nogal
	dei	Entity Address City Or Town EntityAddressCityOrTown	Carlsbad
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92011
	dei	City Area Code CityAreaCode	(760)
	dei	Local Phone Number LocalPhoneNumber	918-9165
	dei	Security12b Title Security12bTitle	Common Stock, par value $.001 per share
	dei	Trading Symbol TradingSymbol	QLGN
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5052463	shares
CY2023Q2	us-gaap	Cash Cash	1341659	usd
CY2022Q4	us-gaap	Cash Cash	7034434	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	679380	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	538587	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1563399	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1586297	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1278077	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1661220	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	4862515	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	10820538	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	5434	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	5690	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1305970	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1422538	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	498647	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	345087	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5833070	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5845702	usd
CY2023Q2	us-gaap	Goodwill Goodwill	625602	usd
CY2022Q4	us-gaap	Goodwill Goodwill	625602	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18334	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18334	usd
CY2023Q2	us-gaap	Assets Assets	13149572	usd
CY2022Q4	us-gaap	Assets Assets	19083491	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1756183	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	857311	usd
CY2023Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	332617	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	467948	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1980555	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1511856	usd
CY2023Q2	QLGN	Research And Development Grant Liability ResearchAndDevelopmentGrantLiability	151620	usd
CY2022Q4	QLGN	Research And Development Grant Liability ResearchAndDevelopmentGrantLiability	780682	usd
CY2023Q2	us-gaap	Deferred Income Current DeferredIncomeCurrent	94474	usd
CY2022Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	116161	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	257155	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	240645	usd
CY2023Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	965155	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	950722	usd
CY2023Q2	us-gaap	Hedging Liabilities Current HedgingLiabilitiesCurrent	133500	usd
CY2022Q4	us-gaap	Hedging Liabilities Current HedgingLiabilitiesCurrent	788100	usd
CY2023Q2	QLGN	Warrant Liabilities Related Party WarrantLiabilitiesRelatedParty	2010180	usd
CY2022Q4	QLGN	Warrant Liabilities Related Party WarrantLiabilitiesRelatedParty	2834547	usd
CY2023Q2	us-gaap	Convertible Debt ConvertibleDebt	812419	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	60197	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8493858	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8608169	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1168653	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1301919	usd
CY2023Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	28648	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	49056	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	150369	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	357757	usd
CY2023Q2	us-gaap	Liabilities Liabilities	9841528	usd
CY2022Q4	us-gaap	Liabilities Liabilities	10316901	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5052463	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5052463	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4210737	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4210737	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	42952	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	42110	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	112554830	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	110528050	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	131891	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	50721	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110695598	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103385172	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2034075	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7235709	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	1273969	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	1530881	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3308044	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8766590	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13149572	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19083491	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1627031	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1430534	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3234201	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2152563	usd
CY2023Q2	QLGN	Cost Of Product Sales CostOfProductSales	1016542	usd
CY2022Q2	QLGN	Cost Of Product Sales CostOfProductSales	1099677	usd
	QLGN	Cost Of Product Sales CostOfProductSales	2281368	usd
	QLGN	Cost Of Product Sales CostOfProductSales	1928524	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2665849	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2660857	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4380283	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5559608	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1326544	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1506227	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3448095	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3370972	usd
CY2023Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	169223	usd
CY2022Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	305103	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	368337	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	443426	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	5178158	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	5571864	usd
	us-gaap	Operating Expenses OperatingExpenses	10478083	usd
	us-gaap	Operating Expenses OperatingExpenses	11302530	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3551127	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4141330	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7243882	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9149967	usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	440294	usd
CY2022Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	14800	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1478967	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	698042	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-377416	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	4824	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-921652	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	11132	usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	1077287	usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-63302	usd
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-63302	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5680	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-376	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10559	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-341	usd
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-300	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5256	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	19248	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-573015	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	708833	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3545871	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4122082	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7816897	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8441134	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-38182	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5438	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-201959	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6173	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-3507689	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-4127520	usd
	us-gaap	Profit Loss ProfitLoss	-7614938	usd
	us-gaap	Profit Loss ProfitLoss	-8447307	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-43484	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4116	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-304512	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4116	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3464205	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4123404	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7310426	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8443191	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.12
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.35
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.35
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.35
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5052463	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5052463	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3668016	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3668016	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5006050	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5006050	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3599093	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3599093	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5052463	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3668016	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5006050	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3599093	shares
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-3507689	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-4127520	usd
	us-gaap	Profit Loss ProfitLoss	-7614938	usd
	us-gaap	Profit Loss ProfitLoss	-8447307	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-56747	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	65540	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	119473	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	65540	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-3564436	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4061980	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-7495465	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-8381767	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-43484	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-4116	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-304512	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-4116	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3520952	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4057864	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7190953	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8377651	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8766590	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1112582	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	252226	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	176220	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-4107249	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6200369	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	672111	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-56747	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-3507689	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3308044	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16564734	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	4716	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1267166	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-4319787	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13516829	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1844500	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1746816	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	65540	usd
CY2022Q2	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	4000000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	696	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1423282	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-4127520	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	18470143	usd
	us-gaap	Profit Loss ProfitLoss	-7614938	usd
	us-gaap	Profit Loss ProfitLoss	-8447307	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	122523	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	66258	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	116567	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	109803	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-133278	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-75295	usd
	us-gaap	Inventory Write Down InventoryWriteDown	-22992	usd
	us-gaap	Inventory Write Down InventoryWriteDown	-16405	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	906145	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2690447	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1478967	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-698042	usd
	QLGN	Loss On Voluntary Conversion Of Convertible Debt LossOnVoluntaryConversionOfConvertibleDebt	-1077287	usd
	QLGN	Accretion Of Discount On Convertible Debt AccretionOfDiscountOnConvertibleDebt	-787517	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-63602	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8614	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-250201	usd
	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	37390	usd
	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	237930	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-382893	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	548487	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	899753	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	27941	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	357508	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-828229	usd
	QLGN	Increase Decrease In Research And Development Grant Liability IncreaseDecreaseInResearchAndDevelopmentGrantLiability	-613793	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-116756	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-73408	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-42095	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-47345	usd
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-207388	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5562416	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7827798	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	246418	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	63483	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	135354	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-246418	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	71871	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3859	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3859	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5808834	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-7752068	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	115803	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-34228	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7040124	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17538272	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1347093	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9751976	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6293	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3501	usd
	QLGN	Transfers Of Inventory From Equipment Held For Lease TransfersOfInventoryFromEquipmentHeldForLease	83271	usd
	QLGN	Fair Value Of Warrant Liabilities On Date Of Exercise FairValueOfWarrantLiabilitiesOnDateOfExercise	858	usd
	QLGN	Voluntary Conversion Of Convertible Debt Into Common Stock VoluntaryConversionOfConvertibleDebtIntoCommonStock	1112582	usd
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	These warrants were subsequently exercised on September 13, 2022
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zgqLDIIeqsLh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zk47oSzVjO4a">Accounting Estimates</span> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management uses estimates and assumptions in preparing its condensed consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant liabilities, stock-based compensation, amortization and depreciation, inventory reserves, allowances for doubtful accounts and returns, and warranty costs. Actual results could vary from the estimates that were used.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1377323	usd
CY2023Q2	QLGN	Prepaid Manufacturing Expenses PrepaidManufacturingExpenses	51710	usd
CY2022Q4	QLGN	Prepaid Manufacturing Expenses PrepaidManufacturingExpenses	43820	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	65288	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	227451	usd
CY2023Q2	QLGN	Preapaid Research And Development Expenses PreapaidResearchAndDevelopmentExpenses	211337	usd
CY2023Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	11636	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	12626	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1278077	usd
CY2023Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	733964	usd
CY2023Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	726449	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	54584	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	187862	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	679380	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	538587	usd
	us-gaap	Product Warranty Expense ProductWarrantyExpense	41000	usd
CY2023Q2	QLGN	Allowances For Sales Return AllowancesForSalesReturn	28000	usd
CY2022Q2	QLGN	Allowances For Sales Return AllowancesForSalesReturn	10000	usd
	QLGN	Allowances For Sales Return AllowancesForSalesReturn	33000	usd
	QLGN	Allowances For Sales Return AllowancesForSalesReturn	53000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3.0	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1661220	usd
CY2023Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	6921	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4239000	usd
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2023Q2	us-gaap	Prepaid Insurance PrepaidInsurance	938106	usd
CY2023Q2	us-gaap	Product Warranty Expense ProductWarrantyExpense	63000	usd
CY2022Q2	us-gaap	Product Warranty Expense ProductWarrantyExpense	22000	usd
	us-gaap	Product Warranty Expense ProductWarrantyExpense	104000	usd
CY2023Q2	us-gaap	Cash Cash	1300000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110700000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5600000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13200000	usd
CY2023Q3	us-gaap	Cash Cash	5200000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	5800000	usd
CY2023Q3	us-gaap	Cash Cash	5200000	usd
CY2023Q2	us-gaap	Escrow Deposit EscrowDeposit	450000	usd
CY2022Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8800000	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	1027455	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	949796	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	177591	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	200318	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	358353	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	436183	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1563399	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1586297	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5252230	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5043533	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4678583	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4623446	usd
CY2023Q2	QLGN	Fixed Asset Impairments FixedAssetImpairments	-75000	usd
CY2022Q4	QLGN	Fixed Asset Impairments FixedAssetImpairments	-75000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	498647	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	345087	usd
CY2023Q2	us-gaap	Depreciation Depreciation	19000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	24000	usd
	us-gaap	Depreciation Depreciation	37000	usd
	us-gaap	Depreciation Depreciation	48000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	625602	usd
CY2022Q4	us-gaap	Goodwill Goodwill	625602	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	764869	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	752237	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	133070	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	145702	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5833070	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5845702	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4239000	usd
CY2023Q2	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022Q2	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2023Q2	QLGN	Accrued Compensation AccruedCompensation	84000	usd
CY2022Q4	QLGN	Accrued Compensation AccruedCompensation	70000	usd
CY2022Q4	QLGN	Accrued Equipment Held For Lease AccruedEquipmentHeldForLease	154433	usd
CY2023Q2	QLGN	Accrued Franchise Sales And Use Taxes AccruedFranchiseSalesAndUseTaxes	30407	usd
CY2022Q4	QLGN	Accrued Franchise Sales And Use Taxes AccruedFranchiseSalesAndUseTaxes	27531	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4663	usd
CY2023Q2	us-gaap	Interest Payable Current InterestPayableCurrent	50101	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2829	usd
CY2023Q2	QLGN	Accrued License Fees AccruedLicenseFees	100026	usd
CY2022Q4	QLGN	Accrued License Fees AccruedLicenseFees	150130	usd
CY2023Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	484048	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	209303	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	368032	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	238211	usd
CY2023Q2	QLGN	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	523490	usd
CY2022Q4	QLGN	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	322987	usd
CY2023Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	16383	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	13158	usd
CY2023Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	140370	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	137568	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	176777	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	181043	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1980555	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1511856	usd
CY2022Q4	QLGN	Fair Value Adjustment Of Warrant FairValueAdjustmentOfWarrant	3622647	usd
	QLGN	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-1478967	usd
CY2023Q2	QLGN	Fair Value Adjustment Of Warrant FairValueAdjustmentOfWarrant	2143680	usd
CY2022Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.08	pure
CY2023Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	841726	shares
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.32
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1111078	usd
CY2023Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1100000	usd
CY2023Q2	QLGN	Accrued Interest AccruedInterest	383000	usd
	QLGN	Accrued Interest AccruedInterest	945000	usd
CY2023Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	364000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	898000	usd
CY2023Q2	QLGN	Fair Value Adjustments Of Warrant FairValueAdjustmentsOfWarrant	2000000.0	usd
CY2023Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	0	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4565097	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1889121	shares
CY2021Q4	us-gaap	Area Of Land AreaOfLand	22624	sqft
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P61M
CY2021Q4	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	November 1, 2022 to November 30, 2027
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P61M
CY2021Q4	us-gaap	Payments For Rent PaymentsForRent	1950710	usd
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P61M
CY2021Q4	QLGN	Tenant Improvement Allowance TenantImprovementAllowance	339360	usd
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4565097	shares
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	500000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y5M19D
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y3M18D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.089	pure
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	184171	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	379392	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	390773	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	402497	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	379164	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1735997	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	310189	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1425808	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	114000	usd
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	119000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	230000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	233000	usd
CY2022Q2	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	96558	usd
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1111078	usd
CY2023Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	841726	shares
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.32
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4565097	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.02	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0158	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0167	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022Q2	us-gaap	Share Price SharePrice	1.05
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	906145	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2690447	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	60000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	13.20
CY2021	QLGN	Fair Value Of Issuance Cost FairValueOfIssuanceCost	300000	usd
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	219101	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	40.70
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1111078	usd
CY2023Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	841726	shares
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.32

Files In Submission

Name	View Source	Status
qlgn-20230630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
qlgn-20230630_cal.xml	Edgar Link	unprocessable
0001493152-23-028465-index-headers.html	Edgar Link	pending
0001493152-23-028465-index.html	Edgar Link	pending
0001493152-23-028465.txt	Edgar Link	pending
0001493152-23-028465-xbrl.zip	Edgar Link	pending
ex10-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
qlgn-20230630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
qlgn-20230630_def.xml	Edgar Link	unprocessable
qlgn-20230630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$QLGN
Qualigen Therapeutics, Inc. Stock $qlgn

2023 Q4 Form 10-Q Financial Statement

#000149315223028465 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QLGN Qualigen Therapeutics, Inc. Stock $qlgn

2023 Q4 Form 10-Q Financial Statement

#000149315223028465 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QLGN
Qualigen Therapeutics, Inc. Stock $qlgn